 Oxford Biomedica PLC said it signed a new license and supply agreement for its lentiviral vector delivery platform LentiVector with US biotech company Cabaletta Bio, Inc, which is developing engineered T cells designed to treat patients with autoimmune diseases. The agreement gives Cabaletta Bio a non-exclusive license to LentiVector for its application in the US companys leading Chimeric AutoAntibody Receptor CAAR T programme, DSG3-CAART targeting DSG3, and puts in place a multi-year supply agreement, Oxford Biomedica said in a statement. 